rose a day after a judge ruled that a Canadian generic-drug maker has to stop selling its own version of the blood thinner Plavix. The drug accounts for about 20% of Bristol's revenue. Bristol rose 5.5% to $22.94 following the decision.
, Bristol's Plavix marketing partner, was also higher, but its gain was muted by the fact that the company cut its forecast to account for the generics that have already been sold. The drugmaker said its earnings would grow about 2% this year, down from its prior outlook calling for 12% growth. Sanofi was up 1.1% to $45.43.
stock was climbing after the company said its Canadian unit completed the purchase of Rep-Pharm for about $48 million. The company said Rep-Pharm won't be material to its earnings. AmerisourceBergen shares were up 2.6% to $45.31.
was lower after the company said it might sell up to 12.5 million shares. The stock is valued at around $148 million. Shares of Arena were down 2.3% to $11.99.
fell after the company's announcement that James H. McGuire and Thomas E. Hodapp have resigned from the board. The board now consists of Braden Kelly, Gene Terry, Ed Cooperman, CEO John Lettko and recently appointed members Jim Hudak and Sam Schwartz. Shares of ProxyMed declined 4.4% to $4.99.